Otamixaban<\/strong>\u00a0(INN<\/a>) is a\u00a0direct factor Xa inhibitor<\/a>,[1]<\/a><\/sup>\u00a0currently being developed by the French pharmaceutical company\u00a0Sanofi-Aventis<\/a>\u00a0as a treatment for\u00a0acute coronary syndrome<\/a>.<\/p>\n

Methyl (2R<\/em>,3R<\/em>)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate<\/p>\n

Guertin KR, Choi YM (2007).\u00a0“The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development”<\/a>.\u00a0Curr. Med. Chem.<\/em>\u00a014<\/strong>\u00a0(23): 2471\u201381.doi<\/a>:10.2174\/092986707782023659<\/a>.\u00a0PMID<\/a>\u00a017979700<\/a>.<\/p>\n

<\/p>\n

Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, (CAS number 193153-04-7) has the International Nonproprietary Name Otamixaban<\/p>\n

The present invention (WO2012130821) 4TH OCT 2012, BENZOIC ACID SALT OF OTAMIXABAN, SANOFI<\/strong>\u00a0relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa and shows the structure illustrated in Formula I:<\/p>\n

 <\/p>\n

<\/p>\n

 <\/p>\n

The benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate according to claims 1 to 5 for use in the treatment of acute myocardial infarction, non-ST elevation myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication, and restenosis.<\/p>\n

http:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2012130821&recNum=1&docAn=EP2012055364&queryString=WO:2012130821%20&maxRec=1<\/p>\n

COPY PASTE LINK<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Otamixaban\u00a0(INN) is a\u00a0direct factor Xa inhibitor,[1]\u00a0currently being developed by the French pharmaceutical company\u00a0Sanofi-Aventis\u00a0as a treatment for\u00a0acute coronary syndrome. Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate Guertin KR, Choi YM (2007).\u00a0“The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development”.\u00a0Curr. Med. Chem.\u00a014\u00a0(23): 2471\u201381.doi:10.2174\/092986707782023659.\u00a0PMID\u00a017979700. Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, (CAS number 193153-04-7) has the International Nonproprietary Name Otamixaban The present… Continue reading WO 2012130821, BENZOIC ACID SALT OF OTAMIXABAN (SANOFI)<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[146],"_links":{"self":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/277"}],"collection":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/comments?post=277"}],"version-history":[{"count":8,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/277\/revisions"}],"predecessor-version":[{"id":294,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/posts\/277\/revisions\/294"}],"wp:attachment":[{"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/media?parent=277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/categories?post=277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amcrasto.theeurekamoments.com\/wp-json\/wp\/v2\/tags?post=277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}